Portfolio intelligence

Start with a CAS. Leave with a decision.

Turn a molecule into a cited Stage-Gate brief: what is known, what remains unresolved, and whether expert diligence should begin now.

Try 114899-77-3 or trabectedin for a reviewed Gate Brief. Another name opens a brief only when an active US Type II DMF matches. A chemical such as acetone is routed toward suppliers instead.

This search is anonymous. brick42 does not set cookies and does not track or keep a record of who is searching. A name outside the reviewed set is sent to NIH PubChem only to identify the chemical, and that lookup is not tied to you. brick42 learns who you are only if you write in.

What the free brief does

The problem is visible. The solution remains expert-led.

01

Identity before intelligence

A valid checksum is not enough. Confirm parent, salt, solvate, and product context before interpreting risk.

02

Directional, never definitive

Containment, supply filings, and launch timing expose evidence and uncertainty rather than manufacturing certainty.

03

A practical next gate

Route/IP screening, CMO capability, and staged NRE work become a scoped brick42 diligence request.